Sab Biotherapeutics Inc (SABS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 86 | 581 | 2,161 | 3,590 | 6,351 |
| Gross Profit | 86 | 581 | 2,161 | 3,590 | 6,351 |
| Operating Expenses | 6,562 | 7,983 | 10,021 | 11,397 | 12,894 |
| Operating Income | -6,477 | -7,402 | -7,860 | -7,807 | -6,543 |
| Interest Expense | 75 | 92 | 88 | 71 | 71 |
| Other Income | -329 | 141 | 99 | 802 | 1,746 |
| Pre-tax Income | -6,881 | -7,354 | -7,849 | -7,076 | -4,868 |
| Income Tax | N/A | N/A | 26 | N/A | -92 |
| Net Income Continuous | -6,881 | -7,354 | -7,875 | -7,076 | -4,776 |
| Net Income | $-6,881 | $-7,354 | $-7,875 | $-7,076 | $-4,776 |
| EPS Basic Total Ops | -1.36 | -1.46 | -1.81 | -1.60 | -1.10 |
| EPS Basic Continuous Ops | -1.36 | -1.46 | -1.78 | -1.64 | -1.11 |
| EPS Diluted Total Ops | -1.36 | -1.46 | -1.81 | -1.60 | -1.10 |
| EPS Diluted Continuous Ops | -1.36 | -1.46 | -1.77 | -1.64 | -1.11 |
| EBITDA(a) | $-5,584 | $-6,479 | $-6,937 | $-6,897 | $-5,762 |